January 30, 2025
Discussions on the Revision of the General Pharmaceutical Legislation (GPL) primarily focus on the incentive frameworks, which are important contributors to innovation. Crucially, the GPL also governs a host of other elements related to drug discovery, regulation and approval which… read more
September 9, 2024
In this guest blog post, Nicholas Cosenza, Head EU Government Affairs at Amgen (EUCOPE member) discuss the importance for the European Union to maintain its biotech sector competitive on the global stage. He also provides leads on the multiple shapes this… read more
August 24, 2023
In this article, Michael N. Abrams and Alexander Natz discuss the current policy initiatives from Europe and the U.S., similarities between them, and implications for the pharmaceutical sector and their standing in a competitive global market. For years, lawmakers have… read more
July 26, 2023
Digitalization is becoming an increasingly more important part of the future of healthcare. It provides an unprecedented opportunity as recent developments in digital innovative technologies such as Artificial Intelligence (AI), machine learning (ML) in medical devices and algorithmic capabilities can… read more
May 3, 2023
In this guest blog, Toon Digneffe, EUCOPE Board Member & Head of Public Affairs and Partnerships – Europe & Canada at Takeda, reflects on the EU Pharmaceutical Package and highlights the importance of multi-stakeholder partnerships to build a sustainable rare… read more